Analyst Reco. Verastem, Inc.

Equities

VSTM

US92337C2035

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
10.9 ^USD	+5.21%		+16.20%	+33.91%

04-18	Verastem Names John Hayslip as Chief Medical Officer	MT
04-18	Verastem Oncology Announces Executive Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Truist Securities Cuts Price Target on Verastem to $34 From $39, Maintains Buy Rating	11-15	MT
B. Riley Starts Verastem at Buy With $21 PT, Notes Likely Accelerated Approval of Avutometinib + defactinib for Low-Grade Serous Ovarian Cancer	27/09/23	MT
RBC Cuts Price Target on Verastem to $32 From $34, Keeps Outperform Rating, Speculative Risk Qualifier	09/08/23	MT
Truist Securities Lowers Price Target on Verastem to $39 From $60, Maintains Buy Rating	11/07/23	MT
RBC Trims Price Target on Verastem to $34 From $36, Maintains Outperform Rating, Speculative Risk Qualifier	03/07/23	MT
Mizuho Upgrades Verastem to Buy From Neutral, Adjusts Price Target to $36 From $24	15/06/23	MT
HC Wainwright Trims Price Target on Verastem to $2 From $3, Keeps Buy Rating	10/05/23	MT
Mizuho Initiates Verastem at Neutral With $2 Price Target	30/03/23	MT
Verastem Says Ovarian Cancer Drug Combination Shows Objective Response Rate of 28% in Phase 2 Study	25/01/23	MT
HC Wainwright Adjusts Verastem's Price Target to $3 From $5, Keeps Buy Rating	07/11/22	MT
RBC Trims Verastem's Price Target to $3 From $5, Keeps Outperform, Speculative Risk Rating	04/11/22	MT
BTIG Adjusts Verastem's Price Target to $5 From $8, Maintains Buy Rating	05/10/22	MT
Alliance Global Reinstates Verastem at Buy, $6 Price Target	07/09/22	MT
RBC Initiates Verastem at Outperform With Speculative Risk Qualifier, $5 Price Target Amid Bullish View on Oncology Opportunity	14/04/22	MT
Truist Securities Initiates Verastem at Buy with $6 Price Target	09/03/22	MT
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021	19/09/21	CI
VERASTEM : HC Wainwright Adjusts Verastem's Price Target to $5 from $4, Keeps Buy Rating	20/07/21	MT
VERASTEM : Alliance Global Starts Verastem at Buy With $6 Price Target	01/07/21	MT
VERASTEM : BTIG Research Upgrades Verastem to Buy From Neutral, $8 Price Target	24/05/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer